Fig. 6.

Monitoring FLT3 kinase activity and inhibition by clinically relevant tyrosine kinase inhibitors (TKI). Dose-response assays were performed using two substrates, FAStide-E (A, C, E) and FAStide-F (B, D, F) in the presence of increasing TKI concentrations (sorafenib, quizartinib and crenolanib). Data show RFU values for each inhibitor normalized to vehicle control (DMSO; representative of 6 independent reactions) and plotted as percent control. IC₅₀ values were calculated from fitting the data to a fixed slope (three parameter) curve in GraphPad Prism. Data points/error bars represent mean ± S.E.